Elanco Animal Health (NYSE:ELAN) Issues Q2 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its second quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.250-0.285 for the period, compared to the consensus EPS estimate of 0.290. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.030-1.090 EPS.

Analyst Upgrades and Downgrades

Several research firms have commented on ELAN. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, April 27th. Leerink Partners raised their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average target price of $27.90.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $2.39 during midday trading on Thursday, hitting $23.79. The company’s stock had a trading volume of 5,833,868 shares, compared to its average volume of 4,995,441. The stock has a market capitalization of $11.83 billion, a price-to-earnings ratio of -49.62, a PEG ratio of 2.93 and a beta of 1.69. The stock’s 50 day simple moving average is $23.85 and its 200 day simple moving average is $23.33. Elanco Animal Health has a fifty-two week low of $11.83 and a fifty-two week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm’s revenue was up 14.9% compared to the same quarter last year. During the same period last year, the business posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts anticipate that Elanco Animal Health will post 1.03 earnings per share for the current year.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 beat and raised full?year outlook — Elanco reported adjusted EPS $0.40 and revenue $1.371B, both above consensus, and raised FY 2026 revenue, adjusted EBITDA and adjusted EPS guidance while increasing its innovation revenue target. This reinforces the company’s revenue growth and margin improvement narrative. Elanco Q1 Results & Guidance
• Positive Sentiment: Product approvals and momentum — Elanco received emergency use authorizations for Negasunt Powder and Tanidil, supporting the company’s innovation-led growth story and pipeline credibility. Product Momentum Article
• Neutral Sentiment: Underlying results detail — Q1 revenue rose ~15% YoY (10% organic cc); adjusted EBITDA $334M (24.5% margin); reported net income $57M; adjusted EPS and adjusted EBITDA figures indicate operational progress but GAAP metrics still show limitations. Detailed Results
• Neutral Sentiment: Investor materials available — Earnings slide deck and full call transcript provide management color on product cadence, margin actions and leverage plan for investors doing deeper due diligence. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Q2 EPS guidance misses consensus — Management set Q2 EPS at $0.250–0.285 versus a ~0.290 consensus; this near?term shortfall likely tempered upside despite the stronger FY view. Guidance Details
• Negative Sentiment: Leverage and GAAP profitability remain concerns — Net leverage is still elevated (reported ~3.5x) and the company reports a negative GAAP net margin, so some investors may be cautious until deleveraging and sustained free?cash?flow improvements are clearer. Leverage & Profitability

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds have recently made changes to their positions in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Elanco Animal Health in the first quarter valued at about $2,065,000. Goldman Sachs Group Inc. lifted its stake in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Empowered Funds LLC lifted its stake in shares of Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after buying an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after buying an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Elanco Animal Health by 2,006.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after buying an additional 295,651 shares during the period. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.